First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

2012176 citationsJournal Articlehybrid Open Access

Authors

Cancer Research UK, Roche.

Good health and well-being

Published in: The Lancet Oncology

Volume 13, Issue 11, pp. 1161-1170

Field-Weighted Citation Impact: 19.29